• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, July 30, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

GW researchers receive $2.2 million grant to study HERV expression in cancer

Bioengineer by Bioengineer
November 16, 2016
in Science News
Reading Time: 3 mins read
0
ADVERTISEMENT
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

WASHINGTON (Nov. 16, 2016) – George Washington University (GW) researchers received a $2.2 million grant from the National Cancer Institute to uncover why certain cancer types increase whereas others are unchanged or even decrease in those with HIV infection.

Douglas Nixon, M.D., Ph.D., chair of the Department of Microbiology, Immunology, and Tropical Medicine at the GW School of Medicine and Health Sciences (SMHS), is the principal investigator on the grant. He is supported by Eduardo M. Sotomayor, M.D., director of the GW Cancer Center, which provided seed funding for this research. Nixon also collaborated with Brad Jones, Ph.D., assistant professor of microbiology, immunology, and tropical medicine at GW SMHS, Keith A. Crandall, Ph.D., director of the GW Computational Biology Institute at the Milken Institute School of Public Health at GW, and Gustavo Reyes-Terán, M.D., M.P.H., adjunct professor of microbiology, immunology, and tropical medicine at GW SMHS and head of the Department of Infectious Diseases (CIENI) at the National Institute of Respiratory Infections in Mexico City.

"While I am not primarily a cancer researcher, I believe HIV/AIDS research can provide unique insights into cancer mechanisms and biology," said Nixon. "I believe this project shows the importance of seed funding, but also of cross-disciplinary work – something GW has made a priority, allowing people from different fields to come together and talk to each other in ways many large institutions do not. I am delighted to be joining the cancer research community and to work with the GW Cancer Center."

Over the past decade, Nixon's research team has published extensively on the effect of HIV infection on the expression of human endogenous retroviruses (HERVs), remnants of ancient viruses found in today's DNA. His team has focused on the youngest of these retroviruses, HERV-K (HML-2). Research shows that HERVs also play a role in the pathogenesis of germ cell tumors, prostate and breast cancers, melanoma, and renal cell carcinoma.

Nixon's team, which includes Matthew Bendall, a student researcher in Nixon's and Crandall's labs, developed a novel computational pathway program, "Telescope," to pinpoint where HERVs are transcribed in HIV patients. To get a fuller picture, Nixon's team will use "Telescope" to determine which HERVs are expressed in prostate, breast, and colon cancers, in patients with and without HIV infection, and follow anti-HERV immune responses. Nixon and his research team hypothesize that HIV reactivation of HERVs stimulates anti-HERV immunity, which specifically recognizes HERVs also expressed in certain cancers. They also believe that these HIV-induced HERV specific immune responses target HERVs that are expressed in breast, colon, or prostate cancer.

"We are thrilled to be working with Dr. Nixon at the GW Cancer Center," said Sotomayor. "We believe this research will have major implications for cancer research, and in the future, cancer patients."

###

Media: To interview Dr. Nixon or learn more, please contact Lisa Anderson at [email protected] or 202-994-3121.

About the GW School of Medicine and Health Sciences: Founded in 1824, the GW School of Medicine and Health Sciences (SMHS) was the first medical school in the nation's capital and is the 11th oldest in the country. Working together in our nation's capital, with integrity and resolve, the GW SMHS is committed to improving the health and well-being of our local, national and global communities. smhs.gwu.edu

About the GW Cancer Center The George Washington (GW) Cancer Center is a collaboration between GW Hospital, The GW Medical Faculty Associates, and the GW School of Medicine and Health Sciences to expand GW's efforts in the fight against cancer. The GW Cancer Center also partners with the Milken Institute School of Public Health at GW, and incorporates all existing cancer-related activities at GW, serving as a platform for future cancer services and research development. Learn more about the GW Cancer Center at http://www.smhs.gwu.edu/cancercenter.

About the GW Computational Biology Institute The George Washington (GW) Computational Biology Institute brings together leading faculty in medicine, biology, public health, and computing to harness biological and patient information, open new doors of discovery that have the potential to benefit millions. Learn more about the GW Computational Biology Institute at http://cbi.gwu.edu.

Media Contact

Lisa Anderson
[email protected]
202-994-3121
@GWtweets

http://www.gwu.edu

############

Story Source: Materials provided by Scienmag

Share12Tweet8Share2ShareShareShare2

Related Posts

Multi-Proteomic Analysis Reveals Host Risks in VZV

Multi-Proteomic Analysis Reveals Host Risks in VZV

July 30, 2025
Merbecovirus S2 Vaccines Trigger Cross-Reactive MERS Protection

Merbecovirus S2 Vaccines Trigger Cross-Reactive MERS Protection

July 29, 2025

Cracking the Code of Cancer Drug Resistance

July 29, 2025

Peptidoglycan Links Prevent Lysis in Gram-Negative Bacteria

July 29, 2025
Please login to join discussion

POPULAR NEWS

  • Blind to the Burn

    Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    57 shares
    Share 23 Tweet 14
  • USF Research Unveils AI Technology for Detecting Early PTSD Indicators in Youth Through Facial Analysis

    42 shares
    Share 17 Tweet 11
  • Dr. Miriam Merad Honored with French Knighthood for Groundbreaking Contributions to Science and Medicine

    45 shares
    Share 18 Tweet 11
  • Engineered Cellular Communication Enhances CAR-T Therapy Effectiveness Against Glioblastoma

    35 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Multi-Proteomic Analysis Reveals Host Risks in VZV

Merbecovirus S2 Vaccines Trigger Cross-Reactive MERS Protection

Cracking the Code of Cancer Drug Resistance

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.